It is currently an exciting time for the evolution of medical therapy for Crohn’s disease, although there are no licensed anti-fibrotic agents available. In addition, longitudinal data demonstrate that rates of progression to fibrostenosing disease have not altered despite the widespread use of anti-TNFα drugs. Endoscopic balloon dilatation therefore remains an important aspect in the management of Crohn's disease related strictures yet there are no national recommendations on best practice.


Consequently, we would be grateful if you could complete this very short survey of your practice in relation to endoscopic balloon dilatation. This will be entirely anonymous, there are no mandatory fields and it will take no more than 3 minutes of your time. We hope the results of this UK-wide survey will inform the need for future national guidance. Please access the survey here​ or at


Thank you in advance for your participation. If you have any questions or would like to know more about the survey, please contact Greg Sebepos-Rogers (


Greg Sebepos-Rogers

Roser Vega

Shameer Mehta